Editor’s note: This article is the fourth in an ongoing series.

As drug and medical device manufacturers interact more directly with customers through social media and direct advertising, lawyers in pharmaceutical and medical device litigation and regulation are struggling to ascertain how the new reality of direct-to-consumer marketing will alter liability.